Inclusion Criteria:

- Metastatic castration resistant prostate cancer

- Disease progression during or after docetaxel-containing regimen for mCRPC

- Surgical or medical castration

- WHO performance status < 2

- Age > 18 years

- Adequate bone marrow, liver and renal functions:

Hematology:

- neutrophils > 1.5 x 109/ l

- hemoglobin > 100 g/l

- platelets > 100 x 109/l

Hepatic and renal functions:

- total bilirubin <1 x ULN

- ALAT and ASAT < 2.5 x ULN, alkaline phosphate <6 x ULN.In the presence of extensive
bone disease, alkaline phosphate > 6 x ULN is accepted

- creatinine < 1.5 x ULN (ie NCI CTC-AE grade < 1)

Exclusion Criteria:

- Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks
prior to enrollment

- Prior therapy with radioisotopes

- Other malignant disease (except superficial non-melanoma skin cancer) within the past
5 years

- Serious liver disease

- History of severe hypersensitivity reaction (grade > 3) to polysorbate 80 containing
drugs

- Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450
3A4/5 (a one week wash-out period is necessary for patients who already are on these
treatments)

- Other serious illness or medical condition:

- Serious cardiac disease; ischemic or thromboembolic cardiac disease, pulmonary
emboli, cardiac infarction within 12 months

- Active infection

- Active peptic ulcer, uncontrolled diabetes mellitus or other contraindications for
the use of corticosteroids

- Auto-immune disease (lupus, scleroderma, rheumatoid polyarthritis)

- Active grade > 2 polyneuropathy